Cargando…

An isogenic cell line panel for sequence-based screening of targeted anticancer drugs

We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Ashley L., Wyhs, Nicolas, Sur, Surojit, Ptak, Blair, Popoli, Maria, Dobbyn, Laura, Papadopoulos, Tasos, Bettegowda, Chetan, Papadopoulos, Nickolas, Vogelstein, Bert, Zhou, Shibin, Kinzler, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184558/
https://www.ncbi.nlm.nih.gov/pubmed/35692635
http://dx.doi.org/10.1016/j.isci.2022.104437
_version_ 1784724548135944192
author Cook, Ashley L.
Wyhs, Nicolas
Sur, Surojit
Ptak, Blair
Popoli, Maria
Dobbyn, Laura
Papadopoulos, Tasos
Bettegowda, Chetan
Papadopoulos, Nickolas
Vogelstein, Bert
Zhou, Shibin
Kinzler, Kenneth W.
author_facet Cook, Ashley L.
Wyhs, Nicolas
Sur, Surojit
Ptak, Blair
Popoli, Maria
Dobbyn, Laura
Papadopoulos, Tasos
Bettegowda, Chetan
Papadopoulos, Nickolas
Vogelstein, Bert
Zhou, Shibin
Kinzler, Kenneth W.
author_sort Cook, Ashley L.
collection PubMed
description We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result in complete gene inactivation despite integration of sgRNA at the desired genomic site. A subset of the lines harbored biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterized lines covering 19 frequently lost cancer pathways. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena.
format Online
Article
Text
id pubmed-9184558
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91845582022-06-11 An isogenic cell line panel for sequence-based screening of targeted anticancer drugs Cook, Ashley L. Wyhs, Nicolas Sur, Surojit Ptak, Blair Popoli, Maria Dobbyn, Laura Papadopoulos, Tasos Bettegowda, Chetan Papadopoulos, Nickolas Vogelstein, Bert Zhou, Shibin Kinzler, Kenneth W. iScience Article We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result in complete gene inactivation despite integration of sgRNA at the desired genomic site. A subset of the lines harbored biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterized lines covering 19 frequently lost cancer pathways. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena. Elsevier 2022-05-23 /pmc/articles/PMC9184558/ /pubmed/35692635 http://dx.doi.org/10.1016/j.isci.2022.104437 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cook, Ashley L.
Wyhs, Nicolas
Sur, Surojit
Ptak, Blair
Popoli, Maria
Dobbyn, Laura
Papadopoulos, Tasos
Bettegowda, Chetan
Papadopoulos, Nickolas
Vogelstein, Bert
Zhou, Shibin
Kinzler, Kenneth W.
An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title_full An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title_fullStr An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title_full_unstemmed An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title_short An isogenic cell line panel for sequence-based screening of targeted anticancer drugs
title_sort isogenic cell line panel for sequence-based screening of targeted anticancer drugs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184558/
https://www.ncbi.nlm.nih.gov/pubmed/35692635
http://dx.doi.org/10.1016/j.isci.2022.104437
work_keys_str_mv AT cookashleyl anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT wyhsnicolas anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT sursurojit anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT ptakblair anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT popolimaria anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT dobbynlaura anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT papadopoulostasos anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT bettegowdachetan anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT papadopoulosnickolas anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT vogelsteinbert anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT zhoushibin anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT kinzlerkennethw anisogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT cookashleyl isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT wyhsnicolas isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT sursurojit isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT ptakblair isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT popolimaria isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT dobbynlaura isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT papadopoulostasos isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT bettegowdachetan isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT papadopoulosnickolas isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT vogelsteinbert isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT zhoushibin isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs
AT kinzlerkennethw isogeniccelllinepanelforsequencebasedscreeningoftargetedanticancerdrugs